7. Tranexamic Acid in Postpartum Hemorrhage (WOMAN Trial)

Quick Recap

Cross-cutting protocol — companion to Tranexamic Acid in Trauma protocol, addressing a genuinely distinct population (postpartum hemorrhage) with its own dedicated, very large trial and its own specific timing-dependency finding, plus a recent (2024) prevention-focused trial with an important negative result. Obstetrics System cross-reference.

1. Definition

Primary postpartum hemorrhage (PPH): typically defined as blood loss exceeding 500 mL within 24 hours of vaginal birth, or 1,000 mL after cesarean delivery, or any blood loss associated with hemodynamic instability — the leading cause of maternal death worldwide, responsible for approximately 100,000 deaths annually, with 99% of these deaths occurring in low- and middle-income countries specifically — a global health burden distribution that directly shaped the design and interpretation of the trial evidence below.

Tranexamic acid (TXA) as PPH treatment: administered once PPH is clinically diagnosed, as a distinct clinical scenario from TXA as PPH prevention, given prophylactically at delivery before hemorrhage has occurred — this protocol addresses both, since the evidence base and conclusions differ meaningfully between the two applications (Section 11).

2. Pathophysiology

TXA's mechanism — competitive plasminogen inhibition, blocking plasmin-mediated fibrin breakdown — is identical to its mechanism in trauma (cross-reference Tranexamic Acid in Trauma protocol), targeting the hyperfibrinolytic component of hemorrhage. Postpartum hemorrhage has its own distinct pathophysiological drivers (uterine atony being the most common cause, alongside retained products of conception, genital tract trauma, and coagulopathy) that are largely mechanically/anatomically distinct from trauma-induced coagulopathy — but the terminal common pathway of ongoing, clinically significant bleeding shares the same fibrinolysis-mediated component that TXA specifically addresses, providing the biological rationale for extending trauma-derived TXA evidence (CRASH-2) into this distinct clinical population.

3. Immediate Stabilization (ABCDE) — TXA as a Time-Critical Circulation Intervention

Not a standalone stabilization scenario; TXA administration sits within the Circulation component of postpartum hemorrhage management (cross-reference relevant Obstetrics System protocols):

Checklist:

4. Focused History

• Precise time since delivery and since bleeding onset — directly relevant given the pronounced time-dependency finding (Section 11)
• Mode of delivery (vaginal vs. cesarean) and estimated blood loss
• Baseline hemoglobin/anemia status — relevant given the distinct, separate WOMAN-2 trial addressing this specific population (Section 11)
• Risk factors for postpartum hemorrhage (relevant to the separate prevention-focused evidence, Section 11)

5. Comprehensive System-wise Examination

• Obstetric/gynecologic: source and severity of bleeding, uterine tone assessment
• Cardiovascular: hemodynamic status, degree of shock

POCUS integration: not a primary component of the TXA-specific decision; relevant to broader PPH source assessment per standard obstetric practice.

6. Syndrome Identification — Reframed as Application-Specific Classification

• Clinically diagnosed PPH, treatment indication: the population and scenario studied in the definitive WOMAN trial — TXA administration is supported, with benefit specifically concentrated in early administration (Section 11)
• Prophylactic/universal prevention at delivery, before PPH has occurred: a distinct clinical question from treatment — current evidence does not uniformly support universal prophylactic use (Section 11), though some dedicated prevention trials in specific delivery contexts (vaginal, cesarean) have shown benefit
• Moderate-to-severe anemia specifically, prophylactic use: the specific, high-risk population tested in WOMAN-2 — found no benefit for PPH prevention in this population specifically (Section 11), a genuinely important negative finding in a population that might otherwise seem intuitively likely to benefit most

7. Differential Diagnosis — Not a Traditional Differential

Cross-reference relevant Obstetrics System protocols for the underlying causes of postpartum hemorrhage (uterine atony, retained products, genital tract trauma, coagulopathy); this protocol addresses the TXA administration decision within already-established or anticipated PPH.

8. Severity/Risk Assessment

Time since delivery/bleeding onset: the dominant, most clinically actionable variable, directly paralleling the time-dependency theme established in the Tranexamic Acid in Trauma protocol — benefit was specifically concentrated in administration within 3 hours of birth.

Baseline anemia status: WOMAN-2's specific focus on moderate-to-severe anemia represented a hypothesis that this population, with less physiological reserve to tolerate blood loss, might show the clearest prevention benefit — a reasonable, biologically motivated hypothesis that the trial's negative result specifically did not confirm (Section 11).

9. Investigations — Not a Primary Diagnostic Workup

Relevant "investigation" is accurate, precise documentation of time since delivery/bleeding onset, paralleling the emphasis in the Tranexamic Acid in Trauma protocol.

10. Point-of-Care Ultrasound — Not a Primary Component

11. Evidence-Based Management

WOMAN Trial (2017) — The Definitive, Large-Scale Treatment Trial

• WOMAN trial (WOMAN Trial Collaborators, Lancet 2017): an international, double-blind, placebo-controlled RCT across 193 hospitals in 21 countries, enrolling 20,060 women with a clinical diagnosis of postpartum hemorrhage (following vaginal or cesarean delivery) — randomized to 1 g IV TXA (with a second 1 g dose available if bleeding continued/recurred) or placebo, alongside standard PPH management
• Primary composite outcome (death from all causes or hysterectomy): not significantly different between groups — the trial's primary, pre-specified outcome was negative, a crucial interpretive point paralleling the primary-vs-secondary-outcome caution theme running throughout this library (cross-reference the FLORALI discussion in HFNC vs. NIV protocol, and the CITRIS-ALI discussion in Vitamin C, Thiamine & Hydrocortisone protocol)
• Secondary outcome — death specifically due to bleeding: reduced from 191 deaths (1.9%) to 155 deaths (1.5%), p=0.045 — a modest, only narrowly statistically significant reduction (relative reduction of approximately 30%, per the trial's own framing)
• Time-dependent subgroup finding — the trial's most clinically emphasized result: when TXA was given within 3 hours of birth, death from bleeding was further reduced (1.7% vs. 1.2%, p=0.008; risk ratio 0.69, 95% CI 0.52–0.91) — directly paralleling the time-dependency pattern established in trauma (cross-reference Tranexamic Acid in Trauma protocol's CRASH-2/PATCH-Trauma discussion)
• The trial's own, direct conclusion: “tranexamic acid reduces death due to bleeding in women with post-partum haemorrhage with no adverse effects...tranexamic acid should be given as soon as possible after bleeding onset” — explicitly emphasizing the time-dependency as the central practical takeaway, consistent with the trauma literature's parallel emphasis
• No discernible increase in thromboembolic events, though the trial's own effect estimates for this specific safety outcome were noted as imprecise given the relatively low absolute event rate

A Genuinely Important, Direct Methodological Critique — Worth Taking Seriously

• Independent commentary published in the same journal specifically challenged the strength of the trial's conclusions, despite its very large sample size: the wide confidence interval on the within-3-hour subgroup finding (0.52–0.91) was noted as "lessening the strength of the data to support the use of tranexamic acid"; and critically, when examining the population of patients who died from bleeding specifically, the confidence interval for the relative risk included the null value of 1 (0.65–1.00) — a genuinely important, precise statistical point that complicates a fully confident reading of the trial's headline finding
• A separate, pointed critique from family medicine literature explicitly noted the pattern of de-emphasizing a negative primary outcome in favor of a secondary endpoint: “ignore that the primary outcome was the same in both groups and focus on a secondary end point, which then becomes the tail wagging the dog” — and specifically calculated the number needed to treat as 274 (95% CI 137–18,923) for the overall bleeding-death reduction, a genuinely large NNT reflecting how modest the absolute effect size actually was despite the trial's large sample size and its wide public health influence; the NNT improved to 100 specifically within the 1–3-hour post-delivery administration subgroup
• A further, explicit critique regarding trial design adequacy: independent commentators specifically noted the trial "does not adequately address clinical issues about optimum timing and dose," and drew a direct parallel to persistent, ongoing controversy in the CRASH-2 trauma literature (cross-reference Tranexamic Acid in Trauma protocol) regarding these same open questions — explicitly concluding that TXA "should not constitute a one-size-fits-all approach" and that WOMAN's results represent “only the beginning stages” rather than a fully settled answer
• Practical significance of this critique: this protocol treats WOMAN as a genuinely important, practice-influencing trial (it directly informed WHO's recommendation, Section 21) while explicitly preserving the honest, precise statistical nuance that its effect size is more modest, and its confidence intervals wider, than the trial's dramatic public-health narrative sometimes conveys — a large sample size achieving narrow statistical significance on a secondary outcome, with a null-inclusive CI on the bleeding-death-specific population, is a genuinely different evidentiary picture than a large, unambiguous, primary-outcome-confirmed effect

Individual Patient Data Meta-Analysis — Reinforcing the Core Finding, With an Important Caveat on Scope

• A subsequent systematic review and individual patient data meta-analysis of TXA for postpartum bleeding specifically confirmed no evidence of increased thrombotic risk, and reinforced that TXA "reduces the risk of life-threatening postpartum bleeding" — while explicitly declining to recommend universal use in all women giving birth, instead suggesting consideration specifically "before a diagnosis of postpartum haemorrhage in women at high risk of death" — a notably measured, risk-stratified recommendation rather than a blanket endorsement

WOMAN-2 (2024) — A Genuinely Important Negative Prevention Trial

• WOMAN-2 trial (Lancet 2024): a dedicated, international, double-blind, placebo-controlled RCT specifically testing TXA given within 15 minutes of umbilical cord clamping (a prophylactic, pre-hemorrhage administration strategy) in women with moderate-to-severe anemia — a population specifically selected as hypothetically most likely to benefit from prevention, given reduced physiological reserve to tolerate any blood loss
• Finding: prophylactic TXA did not reduce the risk of clinically diagnosed postpartum hemorrhage in this specific population — a genuinely important negative result that directly tempers any assumption that TXA's treatment-phase benefit (per WOMAN) automatically extends to a universal or even a targeted, high-risk prophylactic strategy
• Practical significance: this represents an important, population-specific boundary on TXA's demonstrated benefit — the treatment-phase evidence (WOMAN) and the prevention-phase evidence (WOMAN-2, in this specific anemic population) point toward genuinely different conclusions, reinforcing that these are conceptually and evidentially distinct clinical questions rather than a single, unified "TXA in obstetric hemorrhage" indication

Other Prevention-Focused Trials — A More Mixed Picture Than WOMAN-2 Alone Suggests

• Separate, dedicated trials examining TXA specifically for prevention of blood loss after vaginal delivery and after cesarean delivery (both published in NEJM, Sentilhes et al., 2018 and 2021 respectively) have contributed additional, delivery-mode-specific evidence to this prevention question — the overall prevention literature remains more heterogeneous and less uniformly conclusive than the treatment-focused WOMAN trial, and should be considered separately by specific delivery context rather than assuming a single, universal prevention conclusion applies across all obstetric scenarios

Practical Synthesis

For clinically diagnosed postpartum hemorrhage (treatment indication), TXA administration is supported by the large, definitive WOMAN trial, with the clearest, most consistently emphasized practical message being early administration — ideally within 3 hours of birth, and as soon as possible after bleeding onset is recognized. This protocol presents this recommendation with appropriate calibration: the trial's primary composite outcome was itself negative, the bleeding-death-specific effect size corresponds to a genuinely large NNT (274 overall, 100 within the 1–3-hour window), and the confidence interval for the bleeding-death population specifically includes the null value — the intervention is reasonable, low-risk (no discernible thrombotic signal), and inexpensive, making the modest but real benefit worth pursuing, but should not be oversold as a dramatic, unambiguous mortality intervention. For prophylactic/preventive use before PPH has occurred, current evidence is more mixed and population-specific: WOMAN-2 found no benefit in moderate-to-severe anemia specifically, arguing against extending the treatment-phase enthusiasm into a universal or even targeted high-risk prophylactic strategy without further, delivery-mode- and population-specific confirmation. Current WHO guidance recommends TXA for all women with a clinical diagnosis of postpartum haemorrhage (the treatment indication), reflecting the WOMAN trial's practice-shaping influence, while prophylactic use remains a more genuinely open, population- and context-dependent question.

12. Organ Support

Cross-reference relevant Obstetrics System protocols for the broader PPH management framework (uterotonics, mechanical/surgical measures, transfusion) this TXA decision sits within; also cross-reference Tranexamic Acid in Trauma protocol for the parallel, mechanistically related evidence base in a different population.

13. Disease-Specific Therapy

• TXA for PPH treatment: 1 g IV (100 mg/mL, administered at approximately 1 mL/min), with a second 1 g dose if bleeding continues after 30 minutes or recurs within 24 hours — given as soon as possible after PPH diagnosis, ideally within 3 hours of birth
• TXA for PPH prevention: current evidence does not support routine, universal prophylactic administration; specific delivery-mode-focused prevention trials (vaginal, cesarean) provide more targeted, context-specific evidence that should inform any prophylactic use consideration rather than blanket extrapolation from the treatment-focused WOMAN trial

14. Consultation Matrix

15. Monitoring Framework

• Clinical: hemodynamic response, ongoing bleeding trajectory
• Time tracking: time from delivery/bleeding onset to TXA administration documented, given the demonstrated time-dependency

16. ICU Bundle Checklist

17. Complications

Early: no discernible increase in thromboembolic events across WOMAN and the subsequent individual patient data meta-analysis, though effect estimates for this specific safety outcome remain relatively imprecise given low absolute event rates

Prevention: appropriate treatment-vs-prevention indication distinction per Section 6

18. Escalation & De-escalation — Not Directly Applicable

Cross-reference relevant Obstetrics System protocols and Massive Transfusion Protocol for the broader PPH escalation framework.

19. ICU Discharge Criteria — Not Applicable

20. Documentation & Medicolegal Checklist

• Time of delivery, bleeding onset, and TXA administration documented
• Treatment (not prevention) indication documented as the basis for TXA use
• Standard PPH management measures documented alongside TXA administration

21. Key Guidelines

• WHO recommendations for the prevention and treatment of postpartum haemorrhage: recommends TXA for all women with a clinical diagnosis of postpartum haemorrhage, directly reflecting the WOMAN trial's influence on international practice standards

22. Landmark Trials

23. Controversies

• WOMAN's headline finding vs. its precise statistical texture is the central controversy this protocol addresses: the trial is widely cited and has directly shaped WHO guidance based on a dramatic public-health narrative ("reduces death due to bleeding"), yet its own primary composite outcome was negative, its bleeding-death-specific confidence interval included the null value, and independent appraisal calculated a genuinely large NNT (274) — this protocol presents both the trial's real, guideline-shaping influence and this precise statistical caution together, consistent with this library's general practice of engaging honestly with the gap between a trial's public narrative and its underlying numbers (a pattern also addressed, from a different angle, in the Vitamin C protocol's treatment of Marik's original findings and the general primary-vs-secondary-outcome theme running throughout this library).
• Treatment vs. prevention remains a genuinely distinct, incompletely resolved question: WOMAN-2's negative prevention finding in moderate-to-severe anemia — a population that seemed intuitively likely to benefit — is a valuable, sobering reminder that a drug's demonstrated treatment-phase benefit does not automatically generalize to prophylactic use, even in a plausibly high-risk, high-benefit subpopulation; this mirrors a structurally similar caution seen in the Tranexamic Acid in Trauma protocol's discussion of the therapeutic time window, where the specific clinical scenario and timing of administration substantially determine whether benefit is realized.
• The parallel, unresolved timing/dosing questions shared with the trauma TXA literature: independent commentary explicitly drew the comparison to ongoing CRASH-2-related controversy (cross-reference Tranexamic Acid in Trauma protocol's discussion of the 2025 PATCH-Trauma time-window refinement) — both bodies of evidence share the theme that "time to administration matters enormously" while leaving open exactly how precisely that window should be defined, and whether laboratory-guided dosing could refine current empiric, fixed-dose practice.

24. References

1. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105-2116.
2. Chassard D, Bouvet L. Administration of tranexamic acid to reduce maternal mortality related to postpartum haemorrhage: comments on the WOMAN trial. Int J Obstet Anesth. 2018;33:89-90.
3. Letson HL, Dobson GP. Tranexamic acid for post-partum haemorrhage in the WOMAN trial [correspondence]. Lancet. 2017;390(10102):1581-1582.
4. Barry HC. Tranexamic acid decreased death from bleeding but not all-cause mortality in women with postpartum hemorrhage. Am Fam Physician. 2017.
5. Ker K, Roberts I, Chaudhri R, et al. Tranexamic acid for postpartum bleeding: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet. 2024.
6. WOMAN-2 Trial Collaborators. The effect of tranexamic acid on postpartum bleeding in women with moderate and severe anaemia (WOMAN-2): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2024;404:1645-1656.
7. Sentilhes L, Winer N, Azria E, et al. Tranexamic acid for the prevention of blood loss after vaginal delivery. N Engl J Med. 2018;379:731-742.
8. Sentilhes L, Sénat MV, Le Lous M, et al. Tranexamic acid for the prevention of blood loss after cesarean delivery. N Engl J Med. 2021;384:1623-1634.
9. WHO recommendations for the prevention and treatment of postpartum haemorrhage. World Health Organisation; Geneva: 2012 (updated).
10. The Washington Manual of Critical Care, 4th ed. 2025 — obstetric hemorrhage chapter.
11. ICU Protocols: A Step-wise Approach, 2nd ed. — obstetric hemorrhage content.